A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
A phase 2 trial of Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) is a phase 2 interventional study registered as NCT06731907 by Merck Sharp & Dohme LLC, with 90 participants planned, started 2025-03-30 and due to reach its primary completion in 2032-03-12. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialA Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.